<code id='8743532E5F'></code><style id='8743532E5F'></style>
    • <acronym id='8743532E5F'></acronym>
      <center id='8743532E5F'><center id='8743532E5F'><tfoot id='8743532E5F'></tfoot></center><abbr id='8743532E5F'><dir id='8743532E5F'><tfoot id='8743532E5F'></tfoot><noframes id='8743532E5F'>

    • <optgroup id='8743532E5F'><strike id='8743532E5F'><sup id='8743532E5F'></sup></strike><code id='8743532E5F'></code></optgroup>
        1. <b id='8743532E5F'><label id='8743532E5F'><select id='8743532E5F'><dt id='8743532E5F'><span id='8743532E5F'></span></dt></select></label></b><u id='8743532E5F'></u>
          <i id='8743532E5F'><strike id='8743532E5F'><tt id='8743532E5F'><pre id='8743532E5F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:8
          Adobe

          What is the best way to fix faulty blood cells, and do so for the most people? That’s the question a horde of gene editing researchers are chasing. A new paper in Science offers an idea. 

          Researchers loaded up lipid nanoparticles, the tiny clusters of fat, with cellular instruction manuals in the form of mRNA — the same basic construction as the Covid mRNA vaccines. The surface of these therapeutic bundles were decorated with antibodies that guide them to hematopoietic stem cells in the bone marrow. Once there, they delivered gene editing technology packed into the mRNA and corrected sickle cell defects in mice and in human cells.

          advertisement

          “What really struck me was, damn, how efficient it is,” said Paula Cannon, a gene therapy researcher at the University of Southern California’s Keck School of Medicine who was not involved with the paper. 

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          A Q&A with the global head of Boehringer Ingelheim's innovation unit
          A Q&A with the global head of Boehringer Ingelheim's innovation unit

          MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Bristol 'take

          MollyFerguson/STATSomeday-afterthoughtsonBristolMyersSquibbacquiringMiratiTherapeutics:Atake-underde